This Week: A smattering of psychedelic company news Dispatch from Horizons New York 2022 Slides & Discussion: The State of Psychedelic Economy and Industry and more… Algernon Pharmaceuticals enters clinical trial agreement with Yale University | Vancouver-based psychedelic drug developer Algernon has inked an investigator-initiated clinical trial agreement with Yale for a Phase 2 study of DMT for…


Previous articleNuminus Launches Psychedelic-Assisted Therapy for Chronic and Serious Medical Illness
Next articleSmall Pharma Receives Approval for First-In-Human Phase I Clinical Trial With SPL028